Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B‐cell lymphoma
The Journal of Pathology: Clinical Research · 2026
DOI: 10.1002/2056-4538.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2026. Verfasst von Wei-Li Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Receptors, CCR5, Lymphoma, Large B-Cell, Diffuse, Biomarkers, Tumor, Macrophages. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Taiwan University Hospital, National Science and Technology Council, National Taiwan University Hospital Yunlin Branch.
Abstract (Originalsprache)
Few studies have evaluated the impact of organ‐specific tumor microenvironments (TMEs) on clinical outcomes in diffuse large B‐cell lymphoma (DLBCL). This study investigated potential molecular markers, the immune cell composition within the TME, and their associations with clinical outcomes in patients with primary intestinal DLBCL (PI‐DLBCL). We initially analyzed RNA expression in tumor cells from 19 patients with PI‐DLBCL in the experimental cohort. Candidate biomarkers were then assessed in lymphoma tissue from a total of 48 patients in the same cohort, including the 19 with RNA‐expression data, and validated in an independent cohort of 29 patients with PI‐DLBCL. Associations between these markers and clinicopathological features, event‐free survival (EFS), and overall survival (OS) in the two cohorts were analyzed. In the RNA expression panel, CCL5 expression was higher in patients with advanced‐stage PI‐DLBCL and was associated with inferior EFS and OS. Its principal receptor, CCR5, expressed in approximately one‐third of patients, was associated with lower complete response rates to first‐line immunochemotherapy: 50% in the experimental cohort and 10% in the validation cohort and correlated with the 7‐year worse OS rate in both the experimental (49.8% versus 71.4%, p = 0.082) and validation (0% versus 76.2%, p < 0.001) cohorts. In both the experimental and validation cohorts, CCR5‐positive tumors exhibited decreased CD86‐positive (M1‐like) and increased CD206‐positive (M2‐like) macrophage infiltration, consistent with an immunosuppressive TME. Multivariate analyses revealed that CCR5 expression was independently associated with worse EFS ( p < 0.001) and OS ( p = 0.004) in patients with PI‐DLBCL (combined experimental and validation cohorts). CCR5 expression indicates a biologically aggressive subtype of PI‐DLBCL with poor clinical outcomes and M2 macrophage–dominant immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
- Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
- Department of Oncology, National Taiwan University Hospital, Yunlin Branch, Douliu, Taiwan.
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
ORCID-Profile: Chung-Wu Lin, Sung-Hsin Kuo
Förderung
- National Taiwan University Hospital
- National Science and Technology Council
- National Taiwan University Hospital Yunlin Branch
Zitieren
APA
Ma, W. L., Chen, T. Y., Fu, P. A., Chen, J. P., Yao, M., Wang, H. P., Lin, B. R., Lin, C. W., Hsu, C. L., Huang, C. Y., Cheng, A. L., & Kuo, S. H. (2026). Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B‐cell lymphoma. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70112
Vancouver
Ma WL, Chen TY, Fu PA, Chen JP, Yao M, Wang HP, et al. Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B‐cell lymphoma. The Journal of Pathology: Clinical Research. 2026. doi:10.1002/2056-4538.70112
BibTeX
@article{Ma2026,
author = {Ma, Wei-Li and Chen, Tsai-Yun and Fu, Pei-An and Chen, Jo-Pai and Yao, Ming and Wang, Hsiu-Po and Lin, Been-Ren and Lin, Chung-Wu and Hsu, Chia-Lang and Huang, Chung-Yu and Cheng, Ann-Lii and Kuo, Sung-Hsin},
title = {Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B‐cell lymphoma},
journal = {The Journal of Pathology: Clinical Research},
year = {2026},
doi = {10.1002/2056-4538.70112}
}
EUVIMED